Journal
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1002/ijc.34756
Keywords
immunotherapy; kidney cancer; non-clear cell renal cell carcinoma; targeted therapy; tyrosine kinase inhibitors
Categories
Ask authors/readers for more resources
Non-clear cell renal cell carcinoma (nccRCC) is a common subtype of renal cell carcinoma, which mainly affects younger patients and often presents with metastasis. The prognosis of nccRCC is generally worse compared to other subtypes. Clinical trials for this subtype are lacking, leading to limited data on response rates and survival outcomes. Current treatment options for nccRCC are still being investigated, often based on extrapolation from studies on clear-cell RCC.
Non-clear cell renal cell carcinoma (nccRCC) makes up nearly one quarter of all RCC subtypes, commonly impacts younger patients, and is often metastatic at presentation. Compared to clear-cell RCC (ccRCC), nccRCC typically has a worse prognosis in the metastatic setting, with overall survival durations that are similar to 10 months shorter. The nccRCC consists of a wide range of different histological subtypes, the majority of which are composed of papillary, chromophobe, renal medullary carcinoma, translocation RCC, collecting duct carcinoma and unclassified RCC. Most clinical trials have either excluded or only included small numbers of patients with nccRCC; owing to the lack of prospective studies focusing on this population, data on response rates and survival outcomes are lacking. NccRCC treatment is a nascent field with various therapeutic modalities and combinations under investigation, often based on data extrapolated from therapeutic studies in ccRCC. We herein review the use and outcomes of cytotoxic chemotherapy, various combination modalities of tyrosine kinase inhibitors and immune checkpoint inhibitors, and targeted agents. We discuss active ongoing clinical trials for patients with nccRCC and future directions in the treatment of this rare disease. Historically, treatment for nccRCC has been adopted from the standard of care for patients with ccRCC, although these treatments are less effective in the nccRCC population. As we begin to understand the underlying biology of these tumors, clinical trials have been able to slowly accrue and include more patients with various subtypes of nccRCC. There remains much room for improvement in this area of need, but there is hope on the horizon.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available